John William McEvoy

I think there is a lot to like about this from a simplicity perspective. I also appreciate the embrace of ALARA and the recommendation to target BP 120-129 for all. nature.com/articles/s4137… Congrats to @BIHSociety

Obicetrapib is a selective CETPi which ⏬ LDL-C by ~36%. Now in @AmericanHeartJ, we discuss the rational/design of the phase 3 REMBRANDT trial which will examine the effect of obicetrapib + ezetimibe on coronary plaque. sciencedirect.com/science/articl… @JohnKastelein @ProfSNicholls

With contributions from 6 NIPC staff, get the latest insights from the INTERASPIRE study! ‘Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: ’ Read the full article at @NLM_NIH @johnwmcevoy pubmed.ncbi.nlm.nih.gov/40436467/

Join our PgCert in #Cardiac Rehabilitation, with @uniofgalway, and gain advanced skills in •Risk factor management •Behaviour change strategies •Evidence-based rehabilitation Learn more at ⬇️🔗 nipc.ie/education/post…

Insights from Norway on implementing the 2024 European Society of Cardiology Guidelines for elevated blood pressure and hypertension heart.bmj.com/content/early/…

What a pleasure to present on models of obesity care at #ACNAP2025 and to highlight some of the great work being done by @CroiHeartStroke @HSELive & our new @NIPCIRELAND "Peaceplus" project which aims to provide equitable obesity care in Ireland @susanbconnolly

Now in @JACCJournals, @ThijsEijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. jacc.org/doi/10.1016/j.… @MeaganWasfy and I contextualize these results in accompanying editorial @MGHHeartHealth jacc.org/doi/10.1016/j.…

Couldn’t agree more, Ireland’s Integrated Care Cardiologists who work between hospital and the community hubs focussing on CVD Risk, HF and AF would benefit from such a recognised training track @irishcardiacsoc

Now in @JACCJournals, @johnwmcevoy and I discuss approaches to defining hypercholesterolemia and hypertension in an era of CVD risk based treatment allocation. jacc.org/doi/full/10.10…

While this content may seem obvious @ first, I humbly believe the idea is more nuanced than first glance and rather profound. Led by @CianPMcCarthy. @NIPCIRELAND @rblument1 Reflections on Binary Thresholds for Hypercholesterolemia and Hypertension | JACC jacc.org/doi/10.1016/j.…

Not to be missed for all junior #lipid #prevention trainees! Actually not just trainees, all of us

The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes) @American_Heart…

Excited to share this important work showing sodium reduction lowered BP in the context of diabetes. Dietary Patterns, Sodium Reduction, and Blood Pressure in Type 2 Diabetes jamanetwork.com/journals/jamai…

Remember to save the date! This year the National Prevention Conference and the West of Ireland Integrated Diabetes Care Conference come together for the first time to deliver a special two-day conference on the 14th and 15th of November at the Galmont Hotel, Galway.

Watch a round-up from The European Association of Preventive Cardiology (EAPC) 2025 Congress with key presentations from NIPC directors @johnwmcevoy on the new ESC #Hypertension Guidelines and Prof Kornelia Kotseva who shared late-breaking findings from the #INTERASPIRE study.

INTERASPIRE study coordinated by @NIPCIRELAND @GalwayCMNHS, this nice lp(a) paper led by great collaborator and Executive Committee member @ProfKausikRay

Prevalence and Outcomes of #Hypertension subtypes (isolated systolic/diastolic or sys-dias hypertension) from the #NHANES data 🔗 academic.oup.com/ajh/article-ab… 🔒

Congrats @ProfKausikRay & INTERASPIRE team! @NIPCIRELAND @GalwayCMNHS Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies | JACC jacc.org/doi/10.1016/j.…

After 20 years of static development, 3 novel BP ⬇️ therapies were FDA approved in 2024. Now in @JAMACardio, led by ⭐️ @UMassChan student Ritika Revoori, we discuss whether BP surrogate endpoint trials are sufficient for endorsement. @johnwmcevoy jamanetwork.com/journals/jamac…

Thanks @ehj_ed! Shout out also to @drjohnm for his podcast. John clearly 'gets this' issue, both as a clinician and a KOL. Unlike academics who often see few patients, this is something most clinicians understand is v important medscape.com/viewarticle/10… @NIPCIRELAND @GalwayCMNHS